Trials
SPIRE-LL
Trial SPIRE-LL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events ClinicalTrials.gov Identifier: NCT02100514 Aim To assess the efficacy, safety and tolerability of bococizumab in subjects with hyperlipidemia on background statin therapy Study design…
read more »
SPIRE-FH
Trial SPIRE-FH: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia ClinicalTrials.gov Identifier: NCT01968980 Aim To assess the efficacy, safety and tolerability of bococizumab in subjects with heterozygous familial hypercholesterolemia Study design Multicentre double-blind, randomized, placebo-controlled,…
read more »
SPIRE-HR
Trial SPIRE-HR: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects with Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events ClinicalTrials.gov Identifier: NCT01968954 Aim To assess the efficacy, safety and tolerability of Pf-04950615 In subjects with primary hyperlipidemia or mixed dyslipidemia at risk of…
read more »
SPIRE-AI
Trial SPIRE-AI: Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia ClinicalTrials.gov Identifier: NCT02458287 Aim To assess the efficacy, safety, tolerability and subcutaneous administration of bococizumab 150mg and 75mg with a pre-filled pen Study…
read more »
SPIRE-SI
Trial SPIRE-SI: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins ClinicalTrials.gov Identifier: NCT02135029 Aim To demonstrate a superior lipid lowering effect of bococizumab compared to placebo in subjects who are statin intolerant Study design Multicentre, double-blinded, active- and placebo-controlled…
read more »
ALN-PCSsc data suggest 6-month dosing
There was more news from the Phase I trial of ALN-PCSsc, an investigational RNAi therapeutic targeting PCSK9, presented at the last Latebreaker Clinical Trials session. Following initial results, presented at the European Society of Cardiology Congress, London, data reported at the American Heart Association Scientific…
read more »
Bococizumab: Phase II trial
Bococizumab: Phase II trial Reference: Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015; 115:1212–21. Link: http://www.ncbi.nlm.nih.gov/pubmed/25784512 Trial Bococizumab:…
read more »
